In this study, the formation of caffeine/dapsone (CAF/DAP) cocrystals by scalable production methods, such as liquid-assisted grinding (LAG) and spray drying, was investigated in the context of the potential use of processed cocrystal powder for pulmonary delivery. A CAF/DAP cocrystal (1:1 M ratio) was successfully prepared by slow evaporation from both acetone and ethyl acetate. Acetone, ethyl acetate, and ethanol were all successfully used to prepare cocrystals by LAG and spray drying. The powders obtained were characterized by X-ray diffractometry (XRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), and Fourier transform infrared spectroscopy (FTIR). Laser diffraction analysis indicated a median particle size (D 50 ) for spray-dried powders prepared from acetone, ethanol, and ethyl acetate of 5.4 ± 0.7, 5.2 ± 0.1, and 5.1 ± 0.0 μm respectively, which are appropriate sizes for pulmonary delivery by means of a dry powder inhaler. The solubility of the CAF/DAP cocrystal in phosphate buffer pH 7.4, prepared by spray drying using acetone, was 506.5 ± 31.5 μg/mL, while pure crystalline DAP had a measured solubility of 217.1 ± 7.8 μg/mL. In vitro cytotoxicity studies using Calu-3 cells indicated that the cocrystals were not toxic at concentrations of 0.1 and of 1 mM of DAP, while an in vitro permeability study suggested caffeine may contribute to the permeation of DAP by hindering the efflux effect. The results obtained indicate that the CAF/DAP cocrystal, particularly when prepared by the spray drying method, represents a possible suitable approach for inhalation formulations with applications in pulmonary pathologies.
INTRODUCTION
The success of drug therapy is related to an appropriate drug absorption profile, which in turn is influenced by the drug's physicochemical properties, choice of formulation type, and the route of administration (1) . The crystalline structure of an active pharmaceutical ingredient (API) can provide different spatial arrangements, affecting intermolecular interactions, and consequently changing hygroscopicity, stability, solubility, dissolution rate, and drug bioavailability. In this context, there are many studies on different API cocrystal forms (2) (3) (4) , prepared with the intention of improving the primary API's physicochemical properties; furthermore, powder properties such as compaction, flowability, particle size, and shape can also be affected by the crystalline form of the API (5). Karagianni et al. (6) recommended that cocrystals can be a useful alternative approach to enhance specific physicochemical and biopharmaceutical properties of APIs when the approaches of salt or polymorph formation do not meet the expected targets.
Cocrystals are composed of an API and one or more coformers in the same crystal lattice, linked through hydrogen bonds (7) . The coformer may be a neutral guest compound, or another API.
The choice of coformer is a fundamental step in obtaining cocrystals. Both acidic and basic organic substances can be used for this purpose, with acidic substances prevailing. Some examples of the most commonly used coformers are succinic acid, glutaric acid, benzoic acid, salicylic acid, tartaric acid, maleic acid, saccharin, and caffeine (8) (9) (10) .
Alternatively, it is possible to use another API as the coformer to obtain a new crystal lattice in the form of a multidrug cocrystal (MDC), defined as a Bdissociable solid crystalline supramolecular complex comprising two or more therapeutically effective components in a stoichiometric ratio within the same crystal lattice with or without the presence of solvent molecules^ (11) . In some studies, it has been observed that MDCs can provide advantages, as an increased therapeutic effect results by means of synergistic effects. MDCs can also provide enhanced solubility, increased bioavailability, and improved stability of unstable components through intermolecular interactions (12, 13) .
Traditionally, cocrystal preparation techniques involve either solution/solvent evaporation methods or grinding employing a mortar, with or without the addition of small amounts of solvent (14, 15) . The approach of cocrystal preparation by the solution methods presents difficulties related to controlling solvent evaporation, optimal solvent choice, and control of other experimental parameters such as temperature and humidity. The use of cocrystals in pharmaceutical products is already a reality, as evident with the marketed products Entresto® (sacubitril-valsartan), Lexapro® (escitalopram oxalate), and Depakote® (valproate sodium cocrystal with valproic acid) (6) . However, large-scale manufacture and scale-up of cocrystal production by traditional methods may present some challenges.
More recently, techniques such as ball milling and spray drying have been employed as scalable processes for cocrystal manufacturing (16, 17) . In the pharmaceutical industry, grinding methods are the first-choice process to reduce particle size, while the spray-drying method may also be used for solid dispersion formation, solid-state modification, and to control particle size and shape design. The latter technique has been used for engineering particles for different applications, including inhaled formulations (18) .
A good system for inhaled administration must be able to generate an aerosol with a suitable size, preferably in the range between 0.5 and 5 μm, and to present reproducibility between doses (19) (20) (21) (22) . In this regard, spray drying represents a promising technological alternative to obtain cocrystals for pulmonary formulations (21) .
To date, the pulmonary route has mainly been an alternative to the oral route for the treatment of respiratory related diseases (23) (24) (25) . Considering the physiological aspects of inhalation, drugs which are poorly soluble and poorly absorbed by the oral route tend to have better absorption profiles when administered by inhalation through the oropharynx. The alveolar surface area (more than 100 m 2 ), the presence of pulmonary surfactant, good epithelial permeability, and a small aqueous volume at the absorptive surface lead to very rapid absorption into the systemic circulation of small molecules that are deposited in the lungs (23, 26, 27) .
The deposition of an inhaled aerosol is determined by the formulation type and the chosen device. The effectiveness of an inhalation product depends on how much of the administered dose is effectively delivered to the target site (24, 28) . Additionally, from a safety viewpoint, dry powders are required to rapidly dissolve in the lungs (23, 27) . Insoluble, non-digestible particles that deposit in the alveoli can reside in the lungs for years; they are usually sequestered within macrophages and these undissolved solids can induce lung irritation and topical side effects (29) .
Dapsone (DAP) (4,4-diaminodiphenyl sulfone) is a sulfonamide, the first usage of which is reported in the literature dating from 1947 (30) . DAP has a dual mechanism of action, as an antimicrobial agent and as an anti-inflammatory/immunomodulator, making it suitable for the treatment and prevention of infectious diseases caused by pathogens, such as Pneumocystis and Mycobacterium, and for the treatment of chronic inflammatory diseases, such as acne vulgaris by topical administration, and Henoch-Schönlein Purpura (31) (32) (33) (34) (35) . It is currently one of the drugs recommended by the World Health Organization (WHO) for the treatment of leprosy (Mycobacterium leprae infections), in which case it may be combined with rifampicin and clofazimine as a multiple drug therapy (36, 37) . In immunocompromised patients, there are many instances of opportunistic infections, especially cases of pneumonia caused by Pneumocystis carinii or Pneumocystis jiroveci pneumonia. For these cases, DAP is recommended by the American Association of Infectious Diseases and Centers for Disease Control and Prevention as a suitable alternative for the treatment of patients who cannot tolerate trimethoprim-sulfamethoxazole, and its use as an alternative prophylactic regimen therapy for such conditions, alone or in combination with other drugs, is also recommended (33, (38) (39) (40) (41) . In spite of the fact that Pneumocystis carinii and Pneumocystis jiroveci pneumonia affect the airways, DAP is currently only available in dosage forms designed for oral administration. It is well recognized that local respiratory disorders and some systemic diseases may be effectively treated by delivering drugs via the pulmonary route (23, 42) . Furthermore, side effects of DAP delivered by the oral route include hemolysis and methemoglobinemia in 10% of patients (38, 39) .
DAP is classified as a class II drug according to the Biopharmaceutics Classification System and has high permeability and low solubility in water (log P = 0.97) (43) . It exists in four anhydrous forms which are denominated with Roman numerals in the order of their melting points, I 179°C, II 177°C, III transforms to II upon heating and IV ∼ 170°C. Form III is the most stable polymorph of the four forms and is present in commercial products (44) .
The preparation of DAP cocrystals by a slow evaporation solution method has been previously reported by other authors (44) (45) (46) . Jiang and coworkers (46) obtained and characterized DAP cocrystals prepared with sulfanilamide, flavone, lutein, and caffeine as coformers. Caffeine has been widely studied as a coformer and is of particular interest in relation to pulmonary delivery of DAP given the pharmacological effect of caffeine as a strong ventilatory stimulant, improving respiratory muscle strength, which might contribute to a reduction in breathing difficulties associated with Pneumocystis jiroveci pneumonia (41, 47, 48) .
Low-cost and efficient techniques to modulate the therapeutic efficacy of DAP, such as obtaining cocrystals by scalable methods, as well as the study of the viability of administration of DAP by alternative routes, such as the pulmonary route, are of interest for the rejuvenation of this drug.
Thus, the aim of this study was to evaluate the viability of obtaining caffeine/dapsone (CAF/DAP) cocrystals by scalable production methods, such as milling, using liquidassisted grinding (LAG), and spray drying, and to assess the potential for the use of this material in a dry powder inhaler (DPI), as an alternative to the oral route of delivery.
MATERIALS AND METHODS

Materials
Dapsone (DAP) was obtained from G. Amphray Laboratories (Mumbai, India), caffeine (CAF) was purchased from Isofar (Rio de Janeiro, Brazil). All organic solvents were of analytical or HPLC grade and were purchased from SigmaAldrich (St Louis, MO, USA and Arklow, Ireland). Cell culture medium, Dulbecco's modified Eagle medium (DMEM) high glucose, with sodium pyruvate, non-essential amino acids, Hank's balanced salt solution (HBSS), and thiazolyl blue tetrazolium blue (MTT) were also purchased from SigmaAldrich (St Louis, MO, USA and Arklow, Ireland). Cell supplements, fetal bovine serum, and penicillin/streptomycin were purchased from LGC (LGC Biotecnologia, Brazil). Purified and HPLC-grade water was prepared using an Elix 3 connected to a Synergy UV system (Millipore, Feltham, UK). Cell culture flasks 75 cm 3 , 96-well plate, and 12-well plate were purchased from Kasvi (Kasvi, Brazil), and TRANSWELL® polycarbonate filters were purchased from Corning (Corning Inc., Netherlands). Calu-3 cells were obtained from the Cell Bank of Rio de Janeiro (BCRJ).
Cocrystal Preparation
Slow Evaporation DAP and CAF clear solutions (1 mg/mL of DAP), at the molar ratio 1:1, were prepared to study cocrystal preparation. The solvents tested were acetone, acetonitrile, ethyl acetate, ethanol, isopropanol, methanol, and mixtures of acetone/ ethanol (1:1 v/v), acetonitrile/ethanol (2:1 v/v), acetonitrile/ methanol (1:1 v/v), and ethyl acetate/methanol (1:1 v/v). For each solvent, 4 mL of the solution at a concentration of 1 mg/ mL was prepared and filtered into a 5-mL clean vial glass and kept protected from light under ambient laboratory conditions. The flasks were covered with Parafilm® containing 3 holes (~1 mm diameter) to permit solvent evaporation until crystal formation was observed. The crystal lattice structure was analyzed by single-crystal X-ray diffraction (SC-XRD) (see below). The residual material, after total solvent evaporation, was gently pulverized using a mortar and pestle, and the resultant powder was analyzed by powder X-ray diffraction (PXRD) (see below).
Liquid-Assisted Grinding
DAP and CAF at molar ratio (1:1) were ground by liquid-assisted grinding (LAG) in a Retsch PM100 planetary ball mill (Haan, Germany) using three stainless steel balls (20 mm) in each milling jar (50 mL). The maximum sample mass used was 2.5 g. Prior to the LAG process, five drops of the selected solvent were added to the solid mix using a disposable transfer pipette (Fisher Scientific, Hampton, NH, USA). The LAG was carried out at room temperature for 15, 30, and 45 min, with acetone and 30 min with ethanol and ethyl acetate, with rotation speed of 400 rpm (49) . Each formulation was prepared in triplicate and was immediately characterized by PXRD and DSC and stored in a closed amber flask under ambient conditions, with light protection. Before any further analysis, DSC and XRD were repeated to confirm that the solid-state nature of the stored materials was unchanged.
Spray Drying
Spray drying was performed using a Büchi B-290 Mini Spray Dryer (Büchi Labortechnik AG; Flawil, Switzerland) operating in the closed-mode using nitrogen as the atomization and drying gas. The drying gas was recirculated using the B-295 inert loop. Feed solutions of 0.8% (w/v) of DAP and CAF, at 1:1 M ratio, were prepared using acetone, ethanol, or ethyl acetate. In all cases, the air flow rate was 670 l/ h, the inlet temperature was set to 70°C, the feed rate was adjusted to 10.0 mL/min, and the aspirator was operated at 100% (49, 50) . Each formulation was prepared in triplicate, immediately characterized by PXRD, and stored in a closed amber flask under ambient conditions. Before any further analysis, DSC and XRD were repeated to confirm that the solid-state nature of the stored materials was unchanged.
Solid-State Characterization of Different Solid Forms
The SC-XRD crystal analyses were undertaken using an Agilent SuperNova diffractometer 100 K (Agilent Technologies, CA, USA) using monochromated Mo-Kα radiation (λ = 0.71073 Å). Based on the crystal structure obtained by SC-XRD, Mercury software (version 3.3, Cambridge Crystallographic Data Centre, Cambridge, UK) was used to acquire the PXRD diffraction patterns, considering an angle range between 3°and 40°(2 theta) and step size of 0.02°for a Cu-Kα radiation (51) .
PXRD analyses were carried using a Miniflex II Rigaku diffractometer (Rigaku Corporation, Tokyo, Japan) with a Ni-filtered Cu-Kα radiation (1.54 Å) at a voltage of 30 kV and tube current of 15 mA. Samples were scanned between 3 and 40°(2 theta) at a 0.05°/s scanning rate. A minimum of three analyses were performed per sample.
DSC scans of samples were performed using a TA Q200 instrument (TA Instruments, Leatherhead, UK). The thermograms were obtained over a temperature range of 35 to 250°C at a heating rate of 10°C/min under nitrogen gas at a flow rate of 50 mL/min. Sample powders, about 3-4 mg, were placed in aluminum pans, crimped, with one perforation, and placed in the thermal analysis chamber. The unit was calibrated with indium. TGA was performed using a Q50 TA instrument (TA Instruments, Leatherhead, UK). Samples (5-10 mg) were placed into open aluminum pans and analyzed at a constant heating rate of 10°C/min under nitrogen purge. The TA universal analysis software was used to record the mass loss of the analyzed samples. The thermal analyses were conducted in triplicate, and results were analyzed with TA universal analysis 2000 version 4.5A software.
FTIR spectra were recorded in the range from 4000 to 650 cm −1 on a PerkinElmer Spectrum 1 FTIR Spectrometer (PerkinElmer, Massachusetts, USA) equipped with a UATR and a diamond/ZnSe crystal accessory. Spectrum v5.0.1 software was used to assess the spectral data. Each sample was analyzed at least in triplicate.
Particle Characterization
The obtained powders were evaluated for particle size distribution, particle morphology, and specific surface area. Laser diffraction, with a Mastersizer 2000 (Malvern Instruments, Malvern, UK) instrument with Sirocco dry powder air dispersion system, was used to analyze samples produced by LAG and spray drying. The rate of powder dispersion was controlled by adjusting the pressure of the compressed air. Vibrational feed rate of 75% and dispersive air pressure of 2 bar were sufficient to achieve a suitable obscuration between 0.5 and 6%. Data were analyzed based on the D 10 , D 50 , and D 90 .
Surface images of powders were performed by SEM using a Zeiss Ultraplus Thermal Field (Zeiss, Oberkochen, Germany) microscope operating at a voltage of 5 kV. The samples were fixed on aluminum stubs using double-sided adhesive tape and sputter-coated with gold, using a Cressington 108 Sputter Coater (Cressington, UK) under vacuum prior to analysis.
Specific surface area (SSA) of spray-dried powders was measured by gas adsorption using a Micromeritics Gemini VI surface area and pore size analyzer (Micromeritics, Norcross, USA) as previously described (52, 53) . Samples were prepared by purging under nitrogen overnight at 25°C in a Micromeritics FlowPrep (Micromeritics, Norcross, U.S.A.)
Solubility Study
The thermodynamic solubility of cocrystals obtained by LAG and spray drying, physical mixture, and DAP in phosphate buffer (USP 39) pH 7.4 were determined by the shake-flask method. An amount of powder corresponding to three times the estimated DAP saturation concentration reported by Jiang and coworkers (46) was transferred to a 250-mL conical flask containing 150 mL of buffer. The flask contents were then subjected to heating at 37°C in an orbital shaking (150 rpm) incubator 430/RDBP (Ethik Technology, Brazil). At each time point (0.5, 1, 2, 4 and 24 h), a 10-mL sample was collected, immediately filtered through a PVDF 0.45 μm pore size filter, and diluted for quantification of the DAP concentration by HPLC.
High-Performance Liquid Chromatography Method
The HPLC method was based on the method described by Borges et al. (54) . Chromatographic separation was performed using a Kromasil C8 column (150 × 4.6 mm, 5 μm) and the mobile phase consisted of a mixture of 30 mM phosphate buffer pH 7.4 and methanol (85:15), using an HPLC Shimadzu system equipped with a LC-30 AD pump, SIL-30AD autosampler, DAD SPD-M20A UV detector, CTO-20A oven, operated by Labsolution software. The elution was isocratic with a flow rate of 1 mL/min, and components were determined by ultraviolet detection at 273 nm for CAF and at 295 nm for DAP. The sample test and standard solutions injections were made in triplicate. The concentration of the standard solutions of each drug used to construct the calibration curves was in the range 0.5 to 40 μg/mL.
Cell Culture Studies
In vitro cell culture tests using Calu-3 were performed, given the potential application in pulmonary drug delivery. Cytotoxicity, based on a viability assay test, was performed with all cocrystal samples obtained by LAG and spray drying, and the permeability behavior was evaluated for cocrystals obtained by spray drying from acetone.
Calu-3 human bronchial epithelial cells were obtained from the Cell Bank of Rio de Janeiro (BCRJ) and cultured in DMEM supplemented with 1 mM of sodium pyruvate, 10% (v/v) fetal calf serum, 1% (v/v) non-essential amino acids, 2.25 g/L glucose and 1% (v/v) penicillin/streptomycin, and were used between passages 38 and 40. The cultures were maintained in 75 cm 3 culture flasks with 10 mL at 5% CO 2 , 37°C.
Calu-3 human bronchial epithelial cell viability was determined using an MTT assay. Cells were seeded in 96-well plates in a total volume of 200 μL of culture medium at a density of 5 × 10 4 cells/well and incubated in a humidified atmosphere with 5% CO 2 at 37°C for 24 h. After this time, the medium was removed and replaced with 200 μL of fresh medium containing the sample solutions of CAF, DAP, physical mixture CAF/DAP, and cocrystal at 1.0 and 0.1 mM of DAP (n = 4). After 24 h, the solutions were removed and 125 μL of MTT (2.5 mg/mL) in HBSS was added to each well. All plates were incubated at 37°C for 3 h. The supernatant of the MTT solution was removed, and the resulting formazan crystals dissolved by addition of 100 μL of dimethyl sulfoxide (DMSO). The resulting solution was analyzed using a microplate reader with the wavelength set to 530 nm (TP-Reader, Thermoplate, Brazil). Viability was expressed in terms of percentage of the untreated control.
The permeability experiments were performed in the apical to basolateral (A-B) and basolateral to apical (B-A) directions. Cell monolayers were obtained by seeding Calu-3 cells (5 × 10 5 cells/cm 2 ) onto TRANSWELL® polycarbonate filters at a density of 5 × 10 5 cells/cm 2 , with 0.4 μm pore diameter and 1.12 cm 2 of surface area (Corning, Netherlands). Growth medium, 1.5 mL on the basal side compartment and 0.5 mL on the apical side, was replaced with fresh medium every 2 days. The cells were kept in liquidcovered culture (LCC) conditions for 16 days. The transepithelial electrical resistance (TEER) values of the cell layer was measured in a Millicell® ERS-2 (Merck Millipore, Darmstadt, GE) at the 8th, 11th, 14th, and 16th day of culture. To perform the reading of the electrical resistance, the culture medium was replaced with HBSS at the apical and basolateral region. The increase in the values of electrical resistance accompanied the growth of cells in each filter to reach a constant value between 600 and 800 Ω, indicating suitable cellular maturity for the tests (56) .
Based on the results of cytotoxicity studies, three solution samples were evaluated-DAP (0.5 mM); a solution of the CAF/DAP cocrystal obtained by spray drying from acetone (i.e., CAF-DAP(1:1)_SPRAY_Acetone cocrystal, with 0.5 mM DAP) and a solution of the physical mixture of CAF/DAP (1:1) (with 0.5 mM DAP). The solutions were prepared in HBSS buffer and filtered using a 0.22 μm filter under laminar flow to ensure sterility of samples. At the end of the test, the TEER was measured again to determine if there was any damage to the cell monolayer.
Two experiments were performed, using three wells per sample. One experiment was undertaken to evaluate the permeation of DAP from the apical to the basolateral (A-B) chamber and the second experiment evaluated drug permeation from the basolateral to apical (B-A) chamber. In the first test, samples were diluted in HBSS and 0.6 ml was placed in the apical region, while 1.5 ml of fresh HBSS was added to basolateral region. In the second experiment, 1.5 ml of sample was added to the basolateral chamber and 0.5 ml of HBSS was added to the apical chamber. The cells were incubated at 37°C and were then harvested. Aliquots were taken at 0, 30 min, 1, 2, 3, and 4 h from the basolateral chamber in the first experiment, and from the apical chamber in the second experiment, with total replacement with HBSS.
The content of DAP was quantified by the HPLC-UV method as previously described. The apparent permeability coefficient (Papp) was calculated using the following equation:
where Papp is the apparent permeability in cm/s, V is the volume of the receiver chamber, A is the surface area of the cell layer (1.12 cm 2 ), C 0 is the initial concentration in the donor chamber, and dC/dt is the permeability rate (amount of DAP traversing the cell layers per unit time, as determined from the steady state accumulation of the solute in the receiver chamber over time) (57) .
The efflux ratio (ER) was calculated using Eq. 2:
RESULTS AND DISCUSSION
Cocrystal Preparation Studies
Slow Evaporation Method
Initially, cocrystals were prepared by the slow solvent evaporation technique, to choose the ideal solvent for the CAF-DAP system, as well as to obtain suitable crystals to be used as a standard for comparison with cocrystals prepared by other methods. The ideal crystal to enable crystalline structure determination by SC-XRD should be sized around 0.1-0.3 mm in all three dimensions, and its preparation requires the use of specific conditions (55) .
In the present study, it was possible to observe a defined crystal habit when the solvents acetone and ethyl acetate were used with CAF as the coformer.
The SC-XRD analysis of CAF-DAP cocrystal obtained by slow evaporation in the presence of ethyl acetate showed that crystals formed had an orthorhombic crystal structure and diffraction pattern parameters a = 8.5613 (6) (Å) b = 15.6676 (9) (Å) c = 32.2872 (19) (Å) α = β = γ = 90°and cell volume 4330.8 (5) (Å 3 ), as previously described and deposited on the Cambridge Crystallographic Data Centre (CCDC) by Jiang et al. (46) .
When the solvent had completely evaporated, the obtained samples were gently ground using a pestle and mortar and the resulting powder was analyzed by PXRD.
Based on the data from the crystalline structure, deposited with the CCDC, it is possible to simulate the diffractogram which should be obtained by PXRD using the Mercury software (CSD, UK) available on the CCDC website. The simulated PXRD pattern analysis showed peaks at 5.3°, 11.0°, 13.0°, 14.0°, 15.1°, and 24.2°(2θ), related to the CAF/DAP (1:1) cocrystal; peaks at 26.6°and 28.2°(2θ) possibly due the shift of peaks at 26.4°and 28.4°from CAF; and peaks at 20.0°and 28.2°(2θ) possibly due the shift of peaks at 20.2°and 29.0°present in DAP, respectively (Fig. 1) .
The crystals obtained using acetone were needle-shaped, which hinders analysis by SC-XRD. However, the dry sample was analyzed by PXRD and the obtained diffractograms corresponded to the diffractogram of the CAF/DAP (1:1) cocrystal simulated using the Mercury software (Fig. 1e) .
The crystal habit obtained by solvent evaporation from ethanol was poorly defined and the dry material analyzed by PXRD showed some peaks related to a CAF/DAP physical mixture, at 19.2°, 20.8°, and 22.35°(2θ), and only one peak related to the cocrystal, at 13.0°(2θ), indicating that cocrystal formation was not complete (Fig. 1g) .
The samples obtained using acetonitrile (Fig. 1f) , isopropanol (Fig. 1i), methanol (Fig. 1j) , acetone/ethanol (1:1) (Fig. 1k) , acetonitrile/ethanol (2:1) (Fig. 1l ) acetonitrile/ (Fig. 1m) , and ethyl acetate/methanol (1:1) (Fig. 1n) exhibited an undefined crystal habit, and the PXRD patterns showed them to be similar to that of a CAF/DAP physical mixture, showing that the cocrystal was not formed.
Liquid-Assisted Grinding and Spray-Drying Methods
Based on PXRD results (Fig. 1) , which indicated cocrystal formation on slow evaporation from acetone, ethanol, and ethyl acetate, these three solvents were selected to progress with LAG and spray-drying studies.
Initially, equimolar proportions of CAF/DAP (1:1) were ground for 15, 30, and 45 min using acetone as the added solvent (49) . Ground samples were analyzed by PXRD and showed cocrystal peaks at 5.3°, 11.0°, 13.0, 14.0°, 15.1°, and 24.2°(2θ) (Fig. 2a) . DSC analysis (Fig. 2b) also indicated that the CAF/DAP (1:1) cocrystal was formed by LAG, and only a single endothermic peak (at T m = 176.6 ± 0.2°C, ΔH f 104.1 ± 1.2 J/g) was observed for all three samples (milled for the three different time periods), which was consistent with the previously reported value for the melting point of the cocrystal (46) . No statistical difference was observed between the melting points and enthalpies of melting of the three different samples (Table S1 , Supporting information). The intermediate LAG milling time of 30 min was thus selected for LAG studies using ethanol and ethyl acetate solvents and PXRD and DSC (Figs. 3 and 4) confirmed the CAF/DAP (1:1) cocrystal was obtained in both cases.
The spray-drying studies were undertaken using a solution of CAF/DAP (1:1) 0.8% (w/v) in the respective solvents-acetone, ethanol, and ethyl acetate.
PXRD patterns (Fig. 3) indicate the production of a CAF/DAP (1:1) cocrystal in all cases, by both LAG and spray drying (with all three solvents). The difference in intensity of the PXRD diffractograms obtained could be associated with crystal habit differences. DSC analyses of CAF/DAP (1:1) cocrystals obtained by the LAG method, milling for 30 min, using the three different solvents, demonstrated no statistical difference between either the melting point or enthalpy of melting (176.6 ± 0.1°C; ΔH f 103.8 ± 0.6 J/g) (Fig. 4) . In the case of the samples obtained by spray drying however, a single endothermic peak at 175.6 ± 0.1°C ΔH f 98.9 ± 0.2 J/g, 176.3 ± 0.2°C ΔH f 99.8 ± 1.9 J/g J/g, and 175.7 ± 0.1°C ΔH f 96.5 ± 1.6 J/g was observed for samples processed from acetone, ethanol, and ethyl acetate, respectively. The T m and ΔH f for samples obtained using ethanol were statistically different to those processed from the other solvents. The thermograms did not show any evidence of amorphization, as no exothermic events prior to melting were observed (Fig. 4) , and all products melted with decomposition, as observed by TGA analyses (Fig. S1, Supporting information) . Corrigan (56) previously observed that the spray drying process can induce lattice disorder, which may result in no significant changes in PXRD but can alter the fusion point and the enthalpy of melting. . while in the cocrystal, these shift to 3372 and 3356 cm −1 , respectively. It was also possible to observe changes related to the sulfonyl group in the range 1100-1300 cm −1 , as the bands at 1276, 1142, and 1104 cm −1 observed for the physical mixture were shifted to 1283, 1136, and 1099 cm −1 in all cocrystal samples (Fig. S2, Supporting information) . A shift of the band at 1639 to 1644 cm −1 was also observed, relating to the carbonyl bound to the amide of the CAF molecule. As an example, Fig. 5 and Table I show the data obtained for the cocrystal prepared by spray drying from acetone solution.
These changes in the FTIR spectra were expected because the cocrystal interaction between DAP and CAF occurs in the DAP amine portion and CAF carbonyl, related to symmetric axial deformation of the sulfone group present in the DAP molecule.
There are a number of previous reports in the literature of the successful production of pharmaceutical cocrystals by spray drying. Patil et al.. (4) successfully generated a carbamazepine-nicotinamide cocrystal of similar quality by spray drying and LAG. Alhalaweh and Velaga (17) studied the cocrystallization of incongruent and congruent cocrystal systems by spray drying using six different coformers and reported that spray drying was an efficient method to scale-up cocrystals that were also obtained by slow evaporation. Serrano et al. (57) reported the production of the same cocrystal polymorph in different crystal habits using rotary evaporation and spray drying. Thus, while both grinding and spray drying can be considered efficient methods for obtaining cocrystal particles, spray drying is considered to be one of the methods of choice where there is a requirement to produce particles in the low micrometer size range, such as is required for pulmonary drug delivery. Spray drying enables microparticles with a size of less than 5 μm to be produced and allows for particle engineering to modify both size and morphology (52, 58, 59) . Table II shows the particle size distribution of CAF raw material, DAP raw material, a physical mixture of CAF and DAP, and the cocrystals obtained by LAG and spray drying.
The physical mixture had a D 10 , D 50 , and D 90 of 7.9 ± 1.3, 33.9 ± 4.8, and 81.3 ± 1.5 μm, respectively. It can be observed that the D 90 value for the physical mixture is lower than that of CAF alone (D 90 = 431.0 ± 255.8 μm), and of DAP alone (D 90 = 141.8 ± 20.7 μm). The observed difference between the physical mixture and the individual raw materials is possibly due to the preparation of the physical mixture in a mortar and pestle, which can contribute to the size reduction of large particles and/or agglomerates.
The cocrystals obtained by LAG exhibited D 90 values that were higher than that of the physical mixture. Cocrystal samples prepared with acetone, ethanol, and ethyl acetate had D 90 values that were respectively 2.6 times, 4.2 times, and 5.3 times bigger than the D 90 of the physical mixture (Table II) . A possible reason for the increase in particle size is the formation of a new crystalline habit, due to the new intermolecular interactions present in the cocrystal and the formation of agglomerates, which can be observed in the SEM images presented in Figs. 6 and S3. However, it is possible that the particle size and D 90 values could be further reduced by another procedure, such as jet milling, to obtain sizes compatible with pulmonary drug delivery without compromising the formed cocrystal structure (60) .
Powders obtained by spray drying had a median size (D 50 ) of 5.4 ± 0.7 μm, 5.2 ± 0.1 μm and 5.1 ± 0.0 using the Table II solvents acetone, ethanol, and ethyl acetate, respectively (Table II) Comparing the appearance of the physical mixture with the spray-dried and LAG cocrystals, it may be observed that processing resulted in altered crystal habits. The spray-dried cocrystals presented spherical morphologies and rough surfaces (Fig. 5) , while cocrystals obtained by LAG appeared more granular.
The inhalation route represents a promising alternative for the treatment of diseases that affect the respiratory system, including diseases that may be treated with dapsone. According to Wang et al. (61) , in addition to particle size, surface regularity, the presence of pores and particle composition can all influence the region of the respiratory tract in which inhaled particles will deposit. The surface areas of the spray-dried cocrystals were analyzed by the BET method, and the results obtained are shown in Table II . Measured specific surface areas were 2.5 ± 0.5, 2.6 ± 0.4, and 2.5 ± 0.8 m 2 /g for the spray-dried microparticles obtained from acetone, ethanol, and ethyl acetate solutions, respectively. SEM micrographs showed the particles to be smooth, non-porous spheres (Fig. 5 ). Porous and wrinkled or raisin-like particles have been shown to present better in vitro lung deposition in bronchial and alveolar regions of the respiratory tract compared to non-porous particles (50, 59) . Such particle morphologies can be obtained by modifying a multitude of spray-drying process parameters and formulation excipients (52, 53, 62, 63) .
In the present study, the solubility of pure DAP at 37°C in pH 7.4 phosphate buffer was determined to be 217.1 ± 7.8 μg/mL. Borges et al. (54) reported that the solubility of DAP was 134.8 μg/mL in phosphate buffer pH 7.4 at 25°C. No significant difference in the solubility of DAP for all the cocrystal samples obtained by the different methods was observed (Table S2 , Supporting information), and there was a significant increase in DAP solubility (p value < 0.05) for the cocrystal when compared with the pure crystalline form of DAP. The mean solubility value (after 24 h) found for the cocrystal obtained by spray drying CAF/DAP (1:1) from acetone was 506.5 ± 31.5 μg/mL of DAP. Jiang et al. (46) evaluated the solubility of DAP and CAF/DAP cocrystal at 37°C in phosphate buffer pH 6.8 and obtained solubility values of 170 and 310 μg/mL, respectively. The difference in reported solubilities may be related to the pH difference of the buffer solution and/or temperature, which may influence the solubilization of the cocrystal.
In Vitro Cytotoxicity Using Calu-3
Concentrations of 0.1 and 1 mM of DAP were used in cytotoxicity assays, as reported in Table III . The percentage of viable cells in each group treated with samples was compared to the control group (treated only with supplemented DMEM).
It can be observed that all groups showed low cytotoxicity to Calu-3 cells. Apart from one, all tested samples maintained the cell viability at 90% or higher. Only cocrystals obtained by spray drying using ethyl acetate at 0.1 mM of DAP (121.5% of cell viability) and 1.0 mM of DAP (84.9% of cell viability) showed statistically significantly different results (P < 0.05) compared to the control group. Considering that the cytotoxicity test used a solution of the cocrystal, the observed difference is not related to particle characteristics. A dose-response relationship is observed on increasing sample concentration for spray-dried samples, which may be related to residual solvent content. While solid-state characterization did not indicate solvate formation, TGA analysis, between 35 and 80°C indicated residual solvent levels less than 0.2% and future investigations with these samples to elucidate the effect of solvent may be warranted.
Calu-3 cells studies are well established as a means of studying toxicity and permeation of drugs that are administered by inhalation because of their known ability to form monolayers Table III with tight junctions when in cell culture, and for their ability to express the transmembrane conductance regulatory protein (64) (65) (66) . Although the present study concerned the development of a formulation in a powder form that could be directly administered into the airways, the cytotoxicity tests were performed with solutions to be assured of the exact dose of drug that would have contact with the cells. No previous reports of DAP and CAF cytotoxicity using Calu-3 cells were found. Ortiz et al. (67) evaluated the in vivo toxicity of DAP and chitosan microcapsules containing DAP in rats by intratracheal administration using the DP-4 Dry Powder Insufflator™ device (PennCentury-EUA). As a measure of toxicity, the authors used the quantification of the alkaline phosphatase enzyme, which is related to the inflammatory process, present in the bronchoalveolar lavage of the animals. They reported that, after 4 h of administration, elevated levels of this enzyme were not found, which is consistent with our observation of lack of toxicity related to pulmonary delivery of DAP. However, it is recognized that CAF may affect DAP bioavailability and toxicity, and this would need to be investigated in vivo in any future product development studies.
Dapsone Transport across Calu-3 Cell Monolayers
After cytotoxicity testing, a 0.5 mM concentration of DAP in solution was chosen for permeability studies. The cocrystal sample CAF/DAP (1:1) obtained by spray drying from acetone solution was selected for permeability analysis as well as DAP and the physical mixture CAF/DAP (1:1). Table IV shows Papp values obtained in both tests, from the apical to basolateral chamber and basolateral to apical.
Comparing the DAP uptake between cocrystal and physical mixture samples, no significant difference between the samples was observed in either direction-apical to basolateral or basolateral to apical. This behavior was expected since, when present in solution, there is no longer a crystalline structure, and molecules of both the physical mix and cocrystal are freely solubilized in the solvent. However, for both the cocrystal and physical mixture samples, there was greater DAP permeability from the apical towards the basolateral direction than for DAP alone, while in the basolateral to apical direction, there was greater permeability of DAP when present alone in the solution. Thus, in some way, the presence of CAF influences the permeation of DAP, given that the efflux rate (ER) of DAP is 10 times higher in the absence of CAF.
We evaluated the permeability of DAP both from the apical to the basolateral chamber and from basolateral to apical chamber because some studies have reported a significant difference for Papp with respect to the direction of drug transport. This difference is because Calu-3 expresses a few different membrane transporters, and the expression of these drug transporters associated with the efflux pump does not occur uniformly throughout the cell. Nickel et al. (42) and Ong et al. (66) investigated the expression and activity of ATP-binding cassette (ABC) transporters in lung tissue and listed the transporters in the ABC class located in apical and basolateral regions as P-gp, MRP1, MRP2, MRP3, MPR4, MRP5, MRP6, MRP7, and MRP8. The solute linked carrier (SLC) transporters located in the apical region are OCT, OCT1, OCT3, OCTN1, OCTN2, while also present (but whose location is unknown) is the organic anion transporting polypeptide (OATP), OATP1. The expression of these transporters is known to be dependent on passage number, substrate concentration, and temperature.
Seeland et al, (68) studied P-gp substrates and demonstrated that at a concentration of 10 μM, CAF did not interact with P-gp. Using Calu-3 cells, Chappe et al. (69) and Bulteau et al. (70) studied the effect of xanthine derivatives on the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, which is classified as an ABC transporter located in the apical membrane, and observed that some xanthine derivatives are able to activate the CFTR. CAF and its metabolite, theophylline, were found to be able to open the CFRT, which could explain the DAP uptake increase observed with cocrystal and physical mixture samples; however, other permeation mechanisms and the involvement of other transporters cannot be discounted; additional transport studies would be required to elucidate further the exact mechanisms involved.
CONCLUSION
In this study, the use of both spray drying and LAG enabled the production of CAF/DAP cocrystals that present promising characteristics for pulmonary delivery such as particle size distribution (for the spray-dried powders), low to no cytotoxicity in a bronchial epithelial cell model, and improved permeability, relative to DAP alone. In addition, the use of both techniques present options for scalable cocrystal manufacture.
Future work should focus on aerosolization assessment and improvement of morphology and particle size of the CAF/DAP spray-dried powder to confirm its use for pulmonary delivery by means of a dry powder inhaler. 
